--- title: "Off-Target Studies for Gene-Edited Therapies: FDA, China's Drug Route and China's Hospital Route" description: "FDA's 2026 draft, CDE's drug-route guideline and China's new Order 818 filing guides compared: what each asks for in off-target studies, section by section." --- # [Off-Target Studies for Gene-Edited Therapies: FDA, China's Drug Route and China's Hospital Route](https://www.countagen.com/countagen-insights/fda-vs-china-cde-off-target-studies) Written by [Countagen Team](https://www.countagen.com/countagen-insights/author/countagen-team) | Oct 15, 2026, 1:52:11 PM A gene-edited therapy can reach patients in China by two routes, and each route has its own technical texts. The drug route runs through China's Center for Drug Evaluation (CDE). The hospital route, governed by State Council Order No. 818 since May 1, 2026, has filing guides published on April 30, 2026 by the China National Center for Biotechnology Development (CNCBD). In the US, FDA published draft guidance on off-target assessment in April 2026. This post sets the three side by side. Three caveats before the comparison: - **Different scope.** FDA's draft covers genome-edited gene therapy products, ex vivo and in vivo, including epigenome and RNA editors (§III). CDE's 2021 nonclinical guideline covers gene-modified cell therapy products (§2). The CNCBD guides are split by technology. The gene therapy guide covers nucleic acids delivered inside the body. The somatic cell therapy guide covers cells manipulated outside the body, including genetic modification, and returned to the patient (§2 of each). - **Different purpose.** The CNCBD guides apply to clinical research in China that is "not for the purpose of drug registration" (§2). A program heading for NMPA approval follows the drug route. - **None is final or binding.** FDA's draft is marked "not for implementation", and its comment period closed on July 14, 2026. CDE's guideline is a trial version. The CNCBD guides are version 1 and say they will be revised as the field develops. ## Where all three meet All three put off-target work before the clinic and ask for it in human-relevant systems. FDA wants ex vivo studies done in the same cell type that is edited to make the drug product (§VI.A). CDE asks for in vitro on- and off-target activity studies, and for sponsors to consider how species, cell state and cell type affect what the data predicts in patients (§9(3)). The CNCBD gene therapy guide makes the same point from the other direction. Animal and human gene sequences differ, so it asks for a multi-layer, complementary strategy built on human cell lines and bioinformatics (§6.2.3). The somatic cell guide asks for off-target editing risk to be studied and controlled (§5.5.8), and for its effect on cell phenotype and function to be assessed (§6.2.4). ## Where they differ **Whole-genome sequencing.** This is the clearest split, and it runs through China as much as between China and the US. - *CNCBD gene therapy guide (in vivo):* for DNA editing, whole-genome sequencing "should" be used for off-target analysis, combined with prediction algorithms and validation methods, and off-target frequency thresholds should be quantified (§6.2.3). - *CDE (ex vivo cells, drug route):* computational prediction plus deep sequencing of candidate sites "can be used", but the strategy "should still include in vitro whole-genome sequencing comparison" (§9(3)). - *CNCBD somatic cell guide (ex vivo cells, hospital route):* the off-target section doesn't name whole-genome sequencing. It suggests in vitro or in vivo off-target detection methods, with computer predictions as supporting evidence (§6.2.4). Whole-genome sequencing appears elsewhere in the guide, at 50× or more, for genetic stability: copy number and sequence variants, with attention to oncogenes and tumor suppressor genes (§5.5.3). - *FDA:* genome-wide NGS is one way to nominate candidate sites, mainly where no established empirical method exists (§VI.C). Its confirmation section lists targeted methods (§VI.D) and doesn't ask for whole-genome sequencing. **Confirming candidate sites.** FDA names "probe-based sequence enrichment, targeted sequence amplification, and/or other equivalent methods", recommends testing all nominated sites and allows a justified subset (§VI.D). CDE accepts deep sequencing of predicted sites (§9(3)). The CNCBD gene therapy guide asks for off-target frequency thresholds to be quantified (§6.2.3). **Breadth.** FDA's draft has dedicated sections on topics that neither CDE's 2021 text nor the CNCBD off-target sections mention: - **Human genetic variation:** in silico analysis against population variant databases (§VII). - **Chromosomal translocations:** NGS-based assessment where double-strand breaks occur (§VIII). The CNCBD somatic guide asks for chromosome structure to be assessed under genetic stability (§5.5.3, §5.5.8), without linking it to editing. - **Amplification bias:** strategies to minimize PCR amplification and primer bias (§IV). - **Sample design:** multiple biological replicates, plus paired unedited and edited samples (§VI.A, §VI.D). **Timing.** FDA expects all recommended off-target and translocation studies to be completed before the original IND, with full reports (§IX). CDE's 2022 CMC guideline for ex vivo gene modification systems asks for gene-modification risks to be controlled at the IND stage. On the hospital route, Order 818 requires nonclinical research to show a technique is safe and effective before clinical research starts (Art. 9). ## Reading the three together The texts don't line up one to one. On whole-genome sequencing, CDE's drug-route guideline and the CNCBD in vivo guide name it for off-target analysis; FDA's draft and the CNCBD somatic cell guide don't ask for it at that step. FDA's sections on genetic variation, translocations and amplification bias have no direct counterpart in either Chinese route. FDA's draft adds that sponsors can use an alternative approach if it satisfies the applicable statutes and regulations. If you're planning an off-target package for a program headed to FDA, China or both, and want to talk through the confirmation step, [get in touch](https://www.countagen.com/contact). ### Sources - FDA, Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing, draft guidance for industry, April 2026 (docket FDA-2026-D-1255) — [fda.gov](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-assessment-genome-editing-human-gene-therapy-products-using-next-generation-sequencing) - Federal Register notice, April 15, 2026 (comment deadline July 14, 2026) — [federalregister.gov](https://www.federalregister.gov/documents/2026/04/15/2026-07285/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing) - CDE, Technical Guideline for Nonclinical Research of Gene-Modified Cell Therapy Products (Trial), Notice 2021 No. 49 — [cnpharm.com](https://www.cnpharm.com/upload/resources/file/2021/12/03/105424.pdf) - CDE, Technical Guideline for CMC Study and Evaluation of ex vivo Gene Modification Systems (Trial), May 2022, English version — [ccfdie.org](https://www.ccfdie.org/en/gzdt/webinfo/2024/12/1732613148289007.htm) - CNCBD, Filing Guide for Clinical Research of New Gene Therapy Technologies (Version 1), April 2026 — [cncbd.org.cn](https://www.cncbd.org.cn/TColumn/Detail/14533) - CNCBD, Filing Guide for Clinical Research of New Somatic Cell Therapy Technologies (Version 1), April 2026 — [cncbd.org.cn](https://www.cncbd.org.cn/TColumn/Detail/14536) - State Council Order No. 818, Regulations on the Administration of Clinical Research and Clinical Translation of New Biomedical Technologies (2025) — [gov.cn](https://www.gov.cn/zhengce/content/202510/content_7043790.htm) *Chinese quotes are Countagen's translation.* [View full post](https://www.countagen.com/countagen-insights/fda-vs-china-cde-off-target-studies) ```json { "@context" : "http://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Countagen Team" }, "dateModified" : "2026-10-15T13:54:34.765Z", "datePublished" : "2026-10-15T13:52:11Z", "headline" : "Off-Target Studies for Gene-Edited Therapies: FDA, China's Drug Route and China's Hospital Route", "image" : { "@type" : "ImageObject", "height" : 2166, "url" : "https://147523696.fs1.hubspotusercontent-eu1.net/hubfs/147523696/blog-figures/CompareFig1_FDA_CDE_818.png", "width" : 2800 }, "mainEntityOfPage" : "https://www.countagen.com/countagen-insights/fda-vs-china-cde-off-target-studies", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "height" : 60, "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png", "width" : 60 }, "name" : "Countagen Insights" } } ```